First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Authors
Solomon, BMok, T
Kim, D
Wu, Y
Nakagawa, K
Mekhail, T
Felip, E
Cappuzzo, F
Paolini, J
Usari, T
Iyer, S
Reisman, A
Wilner, K
Tursi, J
Blackhall, Fiona H
Affiliation
Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaIssue Date
2014-12-04
Metadata
Show full item recordAbstract
The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.Citation
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014, 371 (23):2167-77 N Engl J MedJournal
The New England Journal of MedicineDOI
10.1056/NEJMoa1408440PubMed ID
25470694Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1408440
Scopus Count
Collections
Related articles
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
- Authors: Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA
- Issue date: 2013 Jun 20
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
- Authors: Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators
- Issue date: 2017 Aug 31
- Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
- Authors: Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E
- Issue date: 2017 Jul
- Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
- Authors: Cui S, Zhao Y, Dong L, Gu A, Xiong L, Qian J, Zhang W, Niu Y, Pan F, Jiang L
- Issue date: 2016 Jun
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
- Authors: Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T
- Issue date: 2017 Jul 1